As shown in Table 1, no significant difference was shown in age, gender, race, tumor location, differentiation degree, pathological type, tumor size, T stage, the number of metastatic lymph nodes, M stage, CEA level, PNI status, and TD count between the training and validation cohorts (all P > 0.05). Here, CEACAM5 is linked to neoplasm.